Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection. Local targets link to admitted publications; unresolved targets remain external evidence.
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
10.1056/nejmoa1606774 · 2016 · External reference
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
10.1056/nejmoa1801005 · 2018 · External reference
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
10.1056/nejmoa1810865 · 2018 · External reference
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
10.1056/nejmoa1910231 · 2019 · External reference
Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
10.1056/nejmoa1709937 · 2017 · External reference
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
10.1056/nejmoa1809064 · 2018 · External reference
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
10.1016/s0140-6736(19)32222-6 · 2019 · External reference
Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer
10.1056/nejmoa2404873 · 2024 · External reference
EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis
10.1158/1078-0432.ccr-15-3101 · 2016 · External reference
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
10.1126/science.aaa1348 · 2015 · External reference
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
10.1126/science.aar3593 · 2018 · External reference
T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028
10.1200/jco.2018.78.2276 · 2019 · External reference
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
10.1038/s41571-020-0340-z · 2020 · External reference
Lineage plasticity and histological transformation: tumor histology as a spectrum
10.1038/s41422-025-01180-x · 2025 · External reference
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
10.1126/scitranslmed.3002003 · 2011 · External reference
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
10.1038/ncomms7377 · 2015 · External reference
EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes
10.1200/jco.18.01585 · 2019 · External reference
Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
10.1016/j.jtho.2019.06.002 · 2019 · External reference
Lineage-specific intolerance to oncogenic drivers restricts histological transformation
10.1126/science.adj1415 · 2024 · External reference
Comprehensive genomic profiles of small cell lung cancer
10.1038/nature14664 · 2015 · External reference
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
10.1016/j.ccell.2020.12.014 · 2021 · External reference
YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype
10.1016/j.jtho.2020.11.006 · 2021 · External reference
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
10.1016/j.ccell.2024.01.010 · 2024 · External reference
Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation
10.1016/j.jtho.2023.05.008 · 2023 · External reference
Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity
10.1158/2159-8290.cd-20-0913 · 2021 · External reference
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity
10.1038/s41568-025-00803-0 · 2025 · External reference
Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer
10.1158/1078-0432.ccr-19-3563 · 2020 · External reference
Histologic transformation in EGFR-mutant lung adenocarcinomas: mechanisms and therapeutic implications
10.3390/cancers13184641 · 2021 · External reference
SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization
10.1016/j.jtho.2020.09.009 · 2020 · External reference
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
10.1101/gad.314815.118 · 2018 · External reference
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
10.1038/nature22323 · 2017 · External reference
Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer
10.1038/s41586-025-09503-z · 2025 · External reference
MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells
10.1093/jnci/djt184 · 2013 · External reference
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
10.1038/s41568-021-00339-z · 2021 · External reference
Cancer immune evasion through loss of MHC class I antigen presentation
10.3389/fimmu.2021.636568 · 2021 · External reference
Cancer immune escape: the role of antigen presentation machinery
10.1007/s00432-023-04737-8 · 2023 · External reference
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
10.1126/science.aaf1490 · 2016 · External reference
Allele-specific HLA loss and immune escape in lung cancer evolution
10.1158/1557-3265.aacriaslc18-ia23 · 2017 · External reference
Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer
10.1158/0008-5472.can-04-3787 · 2005 · External reference
Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer
10.1158/2159-8290.cd-17-0593 · 2017 · External reference
Mutations associated with acquired resistance to PD-1 blockade in melanoma
10.1056/nejmoa1604958 · 2016 · External reference
Spatial analysis and clinical significance of HLA class-I and class-II subunit expression in non-small cell lung cancer
10.1158/1078-0432.ccr-20-3655 · 2021 · External reference
Immune checkpoint blockade in small cell lung cancer
10.1016/j.lungcan.2019.08.024 · 2019 · External reference
High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity
10.1111/j.1349-7006.1992.tb01974.x · 1992 · External reference
Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC
10.1016/j.jtho.2022.05.014 · 2022 · External reference
IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient small cell lung cancer cells
10.1186/s13046-017-0608-z · 2017 · External reference
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018 · External reference
Cancer immune evasion, immunoediting and intratumour heterogeneity
10.1038/s41577-024-01111-8 · 2025 · External reference
IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade
10.1172/jci91190 · 2017 · External reference
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
10.1016/j.ctrv.2017.11.007 · 2018 · External reference
Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade
10.1158/1078-0432.ccr-19-1868 · 2020 · External reference
Mechanisms driving the immunoregulatory function of cancer cells
10.1038/s41568-022-00544-4 · 2023 · External reference
Regulatory circuits of T cell function in cancer
10.1038/nri.2016.80 · 2016 · External reference
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
10.1038/s41568-024-00761-z · 2025 · External reference
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
10.1038/s41591-018-0136-1 · 2018 · External reference
Phenotype molding of stromal cells in the lung tumor microenvironment
10.1038/s41591-018-0096-5 · 2018 · External reference
Single-cell spatial landscapes of the lung tumour immune microenvironment
10.1038/s41586-022-05672-3 · 2023 · External reference
The biology and function of fibroblasts in cancer
10.1038/nrc.2016.73 · 2016 · External reference
TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
10.1038/nature25501 · 2018 · External reference
TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis
10.1038/nature25492 · 2018 · External reference
Myeloid-derived suppressor cells as regulators of the immune system
10.1038/nri2506 · 2009 · External reference
Targeting macrophages: therapeutic approaches in cancer
10.1038/nrd.2018.169 · 2018 · External reference
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
10.1038/s41577-020-00490-y · 2021 · External reference
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
10.1038/s41392-021-00670-9 · 2021 · External reference
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors
10.1016/j.immuni.2014.12.015 · 2014 · External reference
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
10.1016/j.immuni.2014.10.019 · 2014 · External reference
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
10.1038/s41423-024-01207-0 · 2024 · External reference
Natural killer cell therapies
10.1038/s41586-023-06945-1 · 2024 · External reference
Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer
10.1038/s12276-022-00905-x · 2022 · External reference
An evolutionarily conserved function of Polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer
10.1016/j.ccell.2019.08.008 · 2019 · External reference
PRC2-mediated MHC-I silencing drives immune evasion
10.1038/s41568-019-0219-4 · 2019 · External reference
Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis
10.1016/j.ccell.2017.01.006 · 2017 · External reference
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
10.1126/scisignal.aau2922 · 2019 · External reference
ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs
10.1016/j.celrep.2016.06.081 · 2016 · External reference
ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer
10.1016/j.isci.2021.102953 · 2021 · External reference
Inhibition of LSD1 with Bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing
10.1158/1078-0432.ccr-22-1128 · 2022 · External reference
A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs
10.1038/s41467-022-30416-2 · 2022 · External reference
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
10.1038/ncomms15618 · 2017 · External reference
Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
10.1038/s41467-017-01566-5 · 2017 · External reference
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
10.1126/scitranslmed.aac9459 · 2015 · External reference
DLL3: an emerging target in small cell lung cancer
10.1186/s13045-019-0745-2 · 2019 · External reference
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
10.1016/s1470-2045(16)30565-4 · 2017 · External reference
Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study
10.1016/j.jtho.2021.02.009 · 2021 · External reference
Tarlatamab for patients with previously treated small-cell lung cancer
10.1056/nejmoa2307980 · 2023 · External reference
Tarlatamab in small-cell lung cancer after platinum-based chemotherapy
10.1056/nejmoa2502099 · 2025 · External reference
Antibody-drug conjugates in SCLC: DLL3, B7-H3, TROP2, and beyond
10.1016/j.jtho.2026.103726 · 2026 · External reference
Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer
10.1080/13543784.2025.2512566 · 2025 · External reference
ABBV-011, a novel, calicheamicin-based antibody-drug conjugate, targets SEZ6 to eradicate small cell lung cancer tumors
10.1158/1535-7163.mct-21-0851 · 2022 · External reference
